- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01406431
Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects
January 1, 2013 updated by: JW Pharmaceutical
A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatin and Valsartan Co-administration and Livalo® Fixed Combination Drug in Healthy Male Subjects
The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male volunteers
- Age 20-55 years at the time of Screening
- BMI 19-26 kg/m2 at the time of Screening
Exclusion Criteria:
- Received other investigational drug within 90 days prior to the first dose of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pitavastatin + Valsartan
Intervention: Drug: Pitavastatin, Valsartan
|
Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
Other Names:
|
Experimental: Livalo fixed combination drug
Intervention: Drug: Livalo® fixed combination drug
|
Livalo® fixed combination drug(1 tablet)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax of study drugs after single oral administration
Time Frame: 0-48hrs
|
0-48hrs
|
AUClast of study drugs after single oral administration
Time Frame: 0-48hrs
|
0-48hrs
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUCinf, Tmax and t1/2β of study drugs after single oral administration
Time Frame: 0-48hrs
|
0-48hrs
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kyun Seop Bae, MD, Asan Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
July 26, 2011
First Submitted That Met QC Criteria
July 28, 2011
First Posted (Estimate)
August 1, 2011
Study Record Updates
Last Update Posted (Estimate)
January 3, 2013
Last Update Submitted That Met QC Criteria
January 1, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Dyslipidemias
- Hyperlipidemias
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Valsartan
- Pitavastatin
Other Study ID Numbers
- JW-PTV-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Pitavastatin, Valsartan
-
JW PharmaceuticalCompletedHypertension | DyslipidemiaKorea, Republic of
-
JW PharmaceuticalRecruitingHypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Korea University Anam HospitalCompletedAtherosclerosis | Neointima | AnginaKorea, Republic of
-
Shaochun.LiBeijing Friendship Hospital; Peking University Third Hospital; Xuanwu Hospital... and other collaboratorsUnknownDyslipidemia | Subclinical hypothyroïdism | ASCVD | StatinChina
-
JW PharmaceuticalChonbuk National University Hospital; Samsung Medical Center; Asan Medical Center and other collaboratorsCompletedto Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia (SIPHON)HbA1c Level Associated With Lipid CompositionsKorea, Republic of
-
Kowa Research Institute, Inc.CompletedHyperlipidemiaUnited States
-
Qingdao Central HospitalNot yet recruitingMyocardial Infarction | HypertensionChina
-
JW PharmaceuticalCompleted
-
Hanlim Pharm. Co., Ltd.Completed